Phase 2, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Immunogenicity of Two Doses of 3?-aminomethylnicotine-P. aeruginosa r Exoprotein A Conjugate Vaccine (NicVAX?) in 2 Different Dosing Schedules in Smokers

Investigator: Victor I. Reus, MD
Sponsor: NABI

Location(s): United States


The purpose of this study is to determine whether vaccination with NicVAX will result in a higher continuous abstinence rate than vaccination with placebo in smokers who want to quit smoking. In addition, two different formulations and dosing schedules will be studied, to select the dose and dosing schedule which generates the highest level of anti-nicotine antibodies.